#RCUS

@oninvest.bsky.social

2 months ago

Citigroup’s 2026 playbook favors tech, healthcare, and financials. Top picks include #ORCL, #NOW, #DOCU in tech; #NBIX, #RCUS, #WAY in healthcare; and #ALLY, #PAYO, #XYZ in financials, driven by earnings strength and improving outlooks.

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio Arcus (NYSE:RCUS) will discontinue the Phase 3 STAR-221 study evaluating domvanalimab-based combination in advanced gastric and esophageal cancers after an Independent Data Monitoring Committee determined the trial met futility at a pre-specified interim overall survival analysis.Arcus will stop STAR-221 and the Phase 2 EDGE-Gastric study, continue patient transition planning, and redirect R&D resources toward casdatifan (HIF-2a inhibitor) and an emerging inflammation & immunology small-molecule portfolio. Arcus reported casdatifan showed robust single-agent activity in >120 patients with late-line ccRCC and plans multiple casdatifan readouts and initiations across 2026, with potential Phase 3 registrational starts in late 2026. Arcus has ~$1B cash and investments, which it expects will fund operations into at least H2 2028.

#RCUS Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

www.stocktitan.net/news/RCUS/arcus-provides...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $18.25...

#RCUS Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

www.stocktitan.net/news/RCUS/arcus-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#RCUS Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

www.stocktitan.net/news/RCUS/arcus-bioscien...

0 0 0 0

Market Wire News

@marketwirenews.com

4 months ago

News; ( NYSE: #RCUS ) Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia Arcus Biosciences (NYSE:RCUS) and Taiho Pharmaceutical announced Taiho exercised its option to obtain an exclusive license to develop and commercialize casdatifan (AB521) in Japan and certain Asian territories (excluding mainland China) under a 2017 option and license agreement.Terms include an option exercise payment, additional payments tied to clinical, regulatory and commercialization milestones, and royalties on net sales if products are approved. Casdatifan is an investigational HIF-2α inhibitor being evaluated in a global registrational Phase 3 study (PEAK-1) combining casdatifan with a VEGFR-targeted TKI versus TKI alone in advanced clear cell renal cell carcinoma (ccRCC).Japan is expected to join PEAK-1 in H1 2026. This marks Taiho's fifth option exercise on an Arcus program and continues the companies' collaboration on casdatifan development.

#RCUS Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

www.stocktitan.net/news/RCUS/taiho-pharmace...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update Arcus Biosciences (NYSE:RCUS) reported Q2 2025 financial results and pipeline updates, highlighting significant progress in its oncology portfolio. The company ended the quarter with $927 million in cash, positioning it well for pipeline advancement. Key developments include the initiation of PEAK-1, a Phase 3 study of casdatifan + cabozantinib in RCC, and eVOLVE-RCC02, a Phase 1b/3 study with AstraZeneca.Financial highlights include revenues of $160 million (up from $39M in Q2 2024), R&D expenses of $139 million, and break-even net income. The revenue increase was primarily driven by a $143 million cumulative catch-up related to etrumadenant program changes.Clinical progress includes promising data from ARC-20 study showing 46% confirmed response rate in RCC patients, with additional data readouts expected in fall 2025 and 2026. The company anticipates R&D expenses to decline from Q4 2025 as domvanalimab Phase 3 costs decrease.

#RCUS Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

www.stocktitan.net/news/RCUS/arcus-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Arcus' Pancreatic Cancer Drug Gets FDA Orphan Status as Phase 3 Trial Nears Full Enrollment Novel CD73 inhibitor shows 15.7-month survival in Phase 1, targets deadliest cancer type. Phase 3 enrollment completing this year. Learn more about this breakthrough.

#RCUS Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

www.stocktitan.net/news/RCUS/arcus-bioscien...

0 0 0 0

Văzdooh

@vazdooh.bsky.social

9 months ago

#RCUS 10C for December & 15C for April. May be a roll. Random biotech shitco ⚠️. Usual volume is low hundreds.

2 0 0 0

StockTitan

@stocktitan.net

9 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response Arcus Biosciences (NYSE:RCUS) reported promising initial data from the ARC-20 study evaluating casdatifan (HIF-2a inhibitor) plus cabozantinib (tyrosine kinase inhibitor) in metastatic kidney cancer patients. The combination demonstrated a 46% confirmed overall response rate in patients with minimum 12-week follow-up. Among 24 efficacy-evaluable patients, 4% achieved complete response, 42% partial response, and 50% stable disease, with only 4% showing disease progression. The safety profile was manageable with no unexpected risks among 42 safety-evaluable patients. Based on these positive results, Arcus plans to initiate two key trials: PEAK-1, a Phase 3 study in immunotherapy-experienced patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line patients.

#RCUS Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

www.stocktitan.net/news/RCUS/initial-data-f...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Arcus Cancer Drug Shows Breakthrough 30% Response Rate in Kidney Cancer Trial, Reports Strong Q1 Earnings New clinical data reveals promising 30% response rate for casdatifan in kidney cancer. Arcus reports $1B cash runway for pipeline advancement. See full trial results.

#RCUS Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

www.stocktitan.net/news/RCUS/arcus-bioscien...

0 0 0 0

The Insiders Fund Hedge Fund Guy

@insomniachedgefund.bsky.social

1 year ago

Insider buying at Arcus Biosciences: $400K worth of shares. $RCUS burning $75M quarterly with $36M revenue vs $111M R&D spend. Clinical stage biotech is the economic equivalent of cash burn. Arcus logo, The Insiders Fund logo

Insider buying at Arcus Biosciences: $400K worth of shares. $RCUS burning $75M quarterly with $36M revenue vs $111M R&D spend. Clinical stage biotech is the economic equivalent of cash burn. #RCUS www.theinsidersfund.com/2025/02/insi...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update Arcus Biosciences (NYSE:RCUS) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its cancer therapy pipeline. The company's lead drug casdatifan showed promising results in Phase 1/1b ARC-20 study for clear cell renal cell carcinoma (ccRCC), with over 30% confirmed overall response rate in two cohorts and favorable safety profile.Key financial metrics include:Cash position of $992 million as of December 31, 2024Q4 2024 revenues of $36 millionR&D expenses increased to $111 million in Q4 2024Net loss of $94 million in Q4 2024The company plans to initiate the Phase 3 PEAK-1 study evaluating casdatifan with cabozantinib in H1 2025, with initial combination data expected mid-2025. Arcus completed a $150 million financing and expects current funding to support pivotal trials through initial readouts.

#RCUS Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

www.stocktitan.net/news/RCUS/arcus-bioscien...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Wed Feb 19th - #CVEO #GB #SEDG #QUAD #RCUS #TNC #XYF #ADEA #CDRO #DMAC #EDIT #GMGI #ITRN #MFH #PMVP #SEDG - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Tue Feb 18th - #TRS #CATO #JELD #KUKE #RCUS #SAR #BPTH #CISO #EGBN #FORA #GLDD #SEPN #SUNE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Major Cancer Drug Development: Arcus Takes Full Control of Breakthrough $5B Treatment After Gilead Exit Arcus gains complete ownership of promising cancer drug casdatifan following Gilead's option expiration, secures $150M funding for Phase 3 trials with positive data

#RCUS Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

www.stocktitan.net/news/RCUS/arcus-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Arcus Bio Raises Massive $150M War Chest: Major Funding Boost for Cancer Drug Development Arcus Biosciences announces $150M public offering of 13.6M shares at $11 each, strengthening its position for casdatifan development and R&D pipeline

#RCUS Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

www.stocktitan.net/news/RCUS/arcus-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Clinical Trial Success: New Kidney Cancer Drug Keeps 87% of Late-Stage Patients Disease-Free Latest trial data reveals impressive 9.7-month progression-free survival and 87% disease control rate for Arcus' novel HIF-2a inhibitor in heavily pretreated patients.

#RCUS New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

www.stocktitan.net/news/RCUS/new-data-demon...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#RCUS Arcus Biosciences to Participate in Two Upcoming Investor Conferences

www.stocktitan.net/news/RCUS/arcus-bioscien...

0 0 0 0

Posts tagged #RCUS